All In Biotech

Drug Trial Radar · NCT01543763

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jun 25, 2012

Primary completion

Jan 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Pamela MunsterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pharmacyclics LLC.; Novartis; Xynomic Pharmaceuticals, Inc.; GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
First posted
Mar 5, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.

Conditions

  • Metastatic Solid Tumors

Interventions

  • PZP115891, PCI-24781Drug

    PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19 PZP115891: oral, 400 - 800 mg qd 28 days per cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: up to 4 weeks
  2. Maximum Tolerated Dose (MTD)Time frame: up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.